BiotechTube
Xiconic Pharmaceuticals

Xiconic Pharmaceuticals

San Diego, United States· Est.
xiconicpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Xiconic Pharmaceuticals is a private, preclinical-stage biotech developing a novel ADC targeting activated matriptase (actM), a protease overexpressed on tumor cells. Founded to commercialize discoveries from Dr. Joseph Bertino, the company's lead candidate, XCN-010, has shown broad tumor-targeting potential in preclinical models. Led by a seasoned management team with vaccine and oncology experience, Xiconic aims to translate its unique tumor-antigen targeting approach into a clinical-stage asset for multiple cancer indications.

Oncology

Technology Platform

Proprietary antibody-drug conjugate (ADC) platform targeting activated matriptase (actM), a tumor-specific cell-surface serine protease. The Matriptimab™ antibody binds specifically to actM, enabling internalization and delivery of a cytotoxic payload (MMAE).

Opportunities

The broad expression of activated matriptase across many epithelial cancers and lymphomas presents a large addressable market.
Success with its first-in-class ADC could establish actM as a validated oncology target, creating platform potential for follow-on therapeutics.
The tumor-specific expression profile offers a compelling rationale for a favorable safety and efficacy profile.

Risk Factors

High translational risk as promising preclinical data may not predict human clinical success.
The company is a single-asset, preclinical-stage entity with high dependency on XCN-010.
It operates in the highly competitive and capital-intensive ADC space against larger, better-funded competitors.

Competitive Landscape

Xiconic competes in the crowded antibody-drug conjugate (ADC) market, dominated by large pharma and biotech companies with approved and late-stage assets. Its differentiation lies in targeting the novel activated matriptase antigen, which is not targeted by any approved therapy. However, it may face indirect competition from other targeted therapies and ADCs in its target indications.

More companies in Biologics / Biosimilars →More companies in United States →